Skip to main content
    A

    AbbVie Inc (ABBV)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $294.64
    -0.39 (-0.13%)

    Market Cap: $521.50B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    AbbVie Inc (ABBV) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    AbbVie (ABBV) trades at 23.0x trailing earnings and 7.9x sales. Its P/E of 23.0x is above its 5-year median of 15.9x. Its forward P/E is 18.2x. The median P/E across 9 similar companies is 20.0x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 26.4% higher over the next year. Its free cash flow yield is 3.6%.

    MultipleValue
    P/E (trailing)23.0x
    Forward P/E18.2x
    Price to sales7.9x
    EV/EBITDA25.5x
    Price to FCF27.6x
    EV/FCF31.3x
    PEG0.6
    FCF yield3.6%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 84.0% above 12.5x and its P/S is 71.7% above 4.6x.

    MultipleCurrent5-year median10-year median
    P/E23.0x15.9x12.5x
    P/S7.9x5.5x4.6x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 9.9x in 2019 to 22.8x in 2025. 2025 was the highest of those years.

    Year endPriceP/EP/SP/B
    2025$228.4922.8x6.6xN/A
    2024$177.7017.6x5.6x93.7x
    2023$154.9713.9x5.0x26.4x
    2022$161.6111.7x4.9x16.6x
    2021$135.4010.7x4.3x15.6x
    2020$107.1510.2x3.9x14.6x
    2019$88.549.9x3.9xN/A
    2018$92.1911.7x4.3xN/A
    2017$96.7117.3x5.5x30.4x
    2016$62.6213.0x4.0x21.9x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ABBV

    What is ABBV's forward P/E ratio?

    AbbVie has a forward P/E ratio of 18.2x.

    Is ABBV stock overvalued?

    GNG's valuation label for ABBV is Overvalued. Its P/E of 23.0x compares with a median of 20.0x across 9 similar companies.

    What is ABBV's price to sales ratio?

    AbbVie has a price to sales ratio of 7.9x.

    What is AbbVie's average P/E ratio over 5 years?

    AbbVie's median P/E over the last 5 years is 15.9x, from 60 month-end values through Oct 2026.

    What is ABBV's PEG ratio?

    AbbVie has a PEG ratio of 0.6.